Scynexis (SCYX) Cash from Restructuring (2014 - 2016)

Scynexis' (SCYX) quarterly Cash from Restructuring came in at -$8000.0 in Q4 2016, up 96.23% on a QoQ basis from -$212000.0 in Q3 2016.

Scynexis (SCYX) Cash from Restructuring (2014 - 2016) Analysis & Trends

Scynexis (SCYX) has 3 years of Cash from Restructuring data on file, last reported at -$8000.0 in Q4 2016.

Quarterly Cash from Restructuring changed N/A year-over-year to -$8000.0 in Q4 2016, while the trailing twelve-month figure through Sep 2017 was -$8000.0 (up 99.39% YoY) and the FY2016 annual result came in at -$2.6 million, changed N/A from the prior year.
Cash from Restructuring grew to -$8000.0 in Q4 2016, from -$212000.0 in the prior quarter.
In the past five years, Cash from Restructuring ranged from a high of $1.5 million in Q2 2015 to a low of -$1.8 million in Q1 2016.
A 3-year average of -$31285.7 and a median of -$212000.0 in 2016 frame the typical range for Cash from Restructuring.
Annual changes were most pronounced in 2015 — Cash from Restructuring surged 436.76% — and 2016, when it slumped 140.69%.
Tracing SCYX's Cash from Restructuring over 3 years: stood at -$389000.0 in 2014, then surged by 436.76% to $1.3 million in 2015, then tumbled by 100.61% to -$8000.0 in 2016.
The last three Cash from Restructuring figures came in at -$8000.0 (Q4 2016), -$212000.0 (Q3 2016), and -$610000.0 (Q2 2016), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Scynexis	61.90 Mn	-52.80 Mn	-

Download Data